Mittal Niti, Tayal Ashish, Kumar Suneel, Dhawan Reevanshi, Goel Nidhi, Mittal Rakesh
Department of Pharmacology, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak 124001, Haryana, India.
Department of Microbiology, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak 124001, Haryana, India.
Antibiotics (Basel). 2024 Jul 19;13(7):673. doi: 10.3390/antibiotics13070673.
(1) Background: Antibiotic surveillance data are crucial to map out strategies to promote their optimal use at hospital and community levels. We conducted a comprehensive analysis of longitudinal trends in antibiotic consumption over 7 years at a core "National Antimicrobial Consumption Network" site in North India. (2) Methods: In-patient antibiotic consumption data (2017-2023) were obtained from the hospital's central drug store and organised as follows: defined daily dose per 100 bed-days; antibiotic consumption as per the WHO access, watch and reserve classification; trends in overall and different antibiotic classes' consumption; paediatric formulations of antibiotics; and hospital's annual expenditure on antibiotics. (3) Results: During the 7-year study period, no significant trend could be observed in the overall antibiotic consumption (average annual percent change, AAPC: 9.22; 95% CI: -16.46, 34.9) and cost (AAPC: 13.55; -13.2, 40.3). There was a higher proportion of the consumption of antibiotics in the "reserve" group from 2021 onwards compared to previous years, but the overall trend over 7 years was not significant (AAPC: 319.75; -137.6, 777.1). Antibiotic combinations, classified under the WHO "not recommended" category, comprised a significant proportion of antibiotics consumed. A remarkably increased consumption of azithromycin and doxycycline was recorded during 2020 and 2021, coinciding with the COVID-19 pandemic. (4) Conclusions: Some recommendations to optimise antibiotic use are promoting the use of narrow spectrum "access" group agents; linking antimicrobial resistance and consumption data to formulate effective therapeutic and prophylactic antibiotic use guidelines; and the adoption of restrictive antibiotic policy.
(1) 背景:抗生素监测数据对于制定在医院和社区层面促进其合理使用的策略至关重要。我们对印度北部一个核心“国家抗菌药物消费网络”站点7年期间抗生素消费的纵向趋势进行了全面分析。(2) 方法:从医院中央药房获取2017 - 2023年住院患者抗生素消费数据,并按以下方式整理:每100床日的限定日剂量;按照世界卫生组织的准入、监测和储备分类的抗生素消费情况;总体及不同抗生素类别的消费趋势;儿科抗生素制剂;以及医院抗生素年度支出。(3) 结果:在7年研究期间,总体抗生素消费(年均变化百分比,AAPC:9.22;95%置信区间:-16.46,34.9)和成本(AAPC:13.55;-13.2,40.3)均未观察到显著趋势。自2021年起,“储备”组抗生素的消费比例高于前几年,但7年的总体趋势不显著(AAPC:319.75;-137.6,777.1)。世界卫生组织“不推荐”类别的抗生素联合用药占所消费抗生素的很大比例。2020年和2021年期间,阿奇霉素和多西环素的消费量显著增加,与新冠疫情同时发生。(4) 结论:优化抗生素使用的一些建议包括促进使用窄谱“准入”组药物;将抗菌药物耐药性和消费数据关联起来以制定有效的治疗和预防性抗生素使用指南;以及采用限制性抗生素政策。